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ABSTRACT Antibodies were raised against two synthetic
peptides whose sequences correspond respectively to the
COOH-terminal end (residues 501-516) of the protein encoded
by the gene for the 8 chain and to a proposed cytoplasmic
region (residues 350-358) of the (3 chain of the acetylcholine
receptor from Torpedo californica. Binding of the COOH-
terminal antibody to the acetylcholine receptor in intact,
receptor-rich vesicles was tested by radioimmunoassay and by
precipitation with immobilized protein A. In both cases, bind-
ing was detected only after treatment of the vesicles with deter-
gent, suggesting that the segment of the receptor that is recog-
nized by this antibody is on the cytoplasmic side of the mem-
brane. Electron microscopy of tissue from Torpedo electric
organ labeled with colloidal gold-conjugated second antibodies
established that both anti-receptor antibodies bind to the cyto-
plasmic surface of the postsynaptic membrane. These experi-
ments give ultrastructural evidence that the COOH-terminal
segment of the 8 chain as well as residues 350-358 of the (3
chain are on the cytoplasmic surface. They strongly support a
model in which each of the receptor subunits crosses the mem-
brane five times and in which one transmembrane segment of
each chain contributes to the formation of a central ion chan-
nel.
The nicotinic acetylcholine receptor (AcChoR) is located in
the postsynaptic membrane of cholinergic nerve terminals at
neuromuscular junctions. It forms a gated ion channel that
permits passage of 104 sodium ions per msec upon agonist
binding (1-3). The receptor is a pentamer of four different
subunits (a-8) with stoichiometry a2f8y8 (4-6). All of the
subunits span the membrane and occupy quasi-equivalent
positions around the ion channel as seen by electron micros-
copy (7). The apparent molecular weights of the mature sub-
units, based on NaDodSO4/PAGE, are 40,000 (a), 49,000
(,3), 60,000 (y), and 65,000 (8) (1, 2); based on the recently
published cDNA sequences of the subunits, however, they
are 53,649 (a), 56,060 (13), 58,053 (y), and 59,792 (8) before
glycosylation or possible proteolytic processing (8-13). The
receptor is glycosylated approximately eight times (14), so
that the estimated total molecular weight is 295,000 (15). The
deduced amino acid sequences reveal striking homology be-
tween the different subunits (6, 13, 15). This homology has
led to the idea that each of the subunits contributes a similar
peptide component to the formation of a central ion channel
(3, 15). The subject of this paper is the topology of the pep-
tide chain within the membrane as it relates to the ion chan-
nel. Several models of peptide folding across the membrane,
having either four, five, or six membrane crossings per sub-
unit, have been suggested (10, 12, 13, 15-18). Because the
NH2 terminus of 8 is in the extracellular portion of the pro-
tein (19), models with four or six membrane crossings orient
both NH2- and COOH termini on the extracellular side of the
membrane. Models with five membrane crossings place the
COOH terminus on the cytoplasmic side. To locate the
COOH terminus, we generated polyclonal antibodies against
a synthetic hexadecapeptide corresponding to the COOH
terminus of the 8 chain, since it has the longest hydrophilic
sequence as predicted from the cDNA sequence. With these
antibodies, we show (i) that the COOH terminal sequence
deduced from the cDNA clone of the 8 subunit is present in
the mature 8 subunit of the acetylcholine receptor and (ii)
that this amino acid sequence lies on the cytoplasmic side of
the membrane. We also raised antibodies to a synthetic pep-
tide corresponding to residues 350-358t of the 8 chain to
further map the topology of the receptor chains with respect
to the membrane. This portion of the mature f3 chain also
was localized to the cytoplasmic side of the membrane as
previously suggested (10, 12, 13, 15, 16, 18, 20, 21). There
must, therefore, be an even number of transmembrane seg-
ments between residue 358 and the COOH terminus. These
results are consistent with our hypothesis of a second, possi-
bly channel-forming segment that crosses the membrane in
this region.
METHODS
Anti-6 COOH Terminus Antibody (Antibody 8-273). The
peptide Ac-Pro-Phe-Glu-Gly-Asp-Pro-Phe-Asp-Tyr-Ser-Ser-
Asp-His-Pro-Arg-Gly-SH, corresponding to the sequence
Ac-[GlyS516]8-subunit-(501-516) (GlyS, thioglycine) of the
517-amino acid 8 subunit, was synthesized by the solid-
phase method (22), starting with tert-butyloxycarbonylthio-
glycine resin (23, 24). The peptide product was purified by
partition chromatography (25) on Sephadex G-50 and char-
acterized by paper electrophoresis, high performance parti-
tion chromatography, and amino acid analysis. The peptide
was selectively coupled at its COOH terminus to bovine se-
rum albumin (BSA) by reaction with silver nitrate/N-hy-
droxysuccinimide (23, 24) as previously described for the
coupling of corticotropinylthioglycine (26) to BSA. Amino
acid analysis of the peptide-BSA conjugate showed that 8
mol of peptide were coupled per mol of BSA.
Three male New Zealand White rabbits were immunized
intradermally with 8 COOH-terminal peptide-BSA conjugate
Abbreviations: AcChoR, acetylcholine receptor; BSA, bovine se-
rum albumin; mAb, monoclonal antibody.
tThe amino acid sequence numbers used are those obtained after
alignment of all four subunits (20).
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in Freund's complete adjuvant (27). To characterize the anti-
serum, a sample of the peptide was treated with silver nitrate
to give Ac-[Gly56]&-subunit-(501-516), which was then ra-
dioiodinated by the chloramine-T method (27). A sensitive
radioimmunoassay capable of detecting 5-10 pg of peptide
has been established by using standard procedures (27). The
antiserum was used at a final dilution of 1:20,000. Peptide
bound to antibody was separated from free peptide by char-
coal adsorption (28). All three rabbits immunized showed
production of antibodies against the peptide. None of the an-
imals showed symptoms of myasthenia gravis.
Antibody Purification. IgG-rich fractions of the collected
rabbit sera were obtained by precipitating the whole sera
with ammonium sulfate at 30% saturation. The resulting pre-
cipitate was washed with a 35%-saturated ammonium sulfate
solution and then dissolved in 20 mM phosphate buffer, pH
7.4. Buffer was adjusted to 0.15 M NaCl/20 mM phosphate,
pH 7.4 (P1/NaCl) and protein was concentrated by using
Amicon Centriflo membrane cones (nominal Mr retention
:25,00). An affinity column was prepared by coupling the
peptide to aminohexyl-Sepharose as previously described
for the preparation of f3-endorphin-Sepharose (29). Whole
serum was applied to the peptide-Sepharose column at room
temperature and washed with 10 column volumes of Pi/
NaCl. The retained fraction was eluted with 100 mM gly-
cine HCl, pH 3.2, containing BSA at 1 mg/ml. Eluate frac-
tions were neutralized immediately with a saturated
Na2HPO4 solution and were concentrated by using the Cen-
triflo cones.
Anti-. Antibody (Antibody (-350). The peptide Thr-Pro-
Ser-Pro-Asp-Ser-Lys-Pro-Thr-Cys was synthesized by Se-
quemat (Boston, MA). The first nine residues reproduce the
sequence 350-358 of the ,3 subunit of the AcChoR. The pep-
tide was coupled to BSA with diazotized benzidine (30) and
injected intradermally into a female New Zealand White rab-
bit. The serum was tested as described for the anti-8 antibod-
ies. Dilutions of 1:100 and 1:1000 were used. There were no
signs of myasthenia gravis in the animal.
The antibody was affinity-purified on a column of peptide-
linked CN-Sepharose (Pharmacia) and eluted with 3 M sodi-
um thiocyanate. After extensive dialysis against P,/NaCl,
the antibodies were concentrated with Aquacide III (Calbio-
chem).
Control Antibodies. Several antibodies were used through-
out this work as controls: monoclonal antibodies (mAbs)
210, 111, and 35 (referred to as L-210, L-111, and L-35), gen-
erated in rats (31, 32), were generously provided by J. Lind-
strom (Salk Institute, La Jolla, CA). mAb 88 (referred to as
F-88) which was generated in mice (33) and a rabbit polyclo-
nal anti-Torpedo californica AcChoR serum were generous-
ly provided by S. Froehner (Dartmouth Medical School,
Hanover, NH).
Immunoblots. Affinity-purified T. californica AcChoR or
a 1% (wt/vol) Triton X-100 extract of tissue that had been
disrupted and washed exactly as for electron microscopy
was electrophoresed on a NaDodSO4/9% polyacrylamide
gel. The proteins were electrophoretically transferred to a
nitrocellulose filter (34). The nitrocellulose filter was cut into
strips and each strip was incubated with first antibody fol-
lowed by 125I-labeled second antibody. Bands were detected
by autoradiography at -70°C on Kodak X-Omat film.
Antibody Binding Assay. In vitro antibody-binding studies
were done using extracellular-side-out AcChoR vesicles (35,
36) in which disulfide bonds had been reduced and carba-
moylmethylated with 2-mercaptoethanol and iodoacetamide
to ensure that all AcChoR was monomeric (37). Vesicle sam-
ples were divided into three aliquots: (i) intact control vesi-
cles, (ii) vesicles permeabilized with 1% saponin but other-
wise intact, and (iii) vesicles solubilized in 1% (wt/vol) Tri-
ton X-100 or 2% (wt/vol) sodium cholate. AcChoR solutions
were then diluted 40-fold with 20 mM phosphate, pH 7.2.
AcChoR, either in vesicles or solubilized (-200 fmol per as-
say), was incubated at room temperature for 3 hr with a
1:200 dilution of antibody (8-273, P-350, F-88, or L-35) in a
final volume of 20 Al. All antibodies showed maximal reac7
tion at this concentration. AcChoR was labeled by addition
of 10 ILI of 59 mM 125I-labeled a-bungarotoxin for 1 hr at
room temperature. After labeling, saponin-permeabilized
vesicles were disrupted by adding 50 Al of 1% Triton X-100
in Pi/NaCl and incubating for 1 hr at room temperature.
P1/NaCl was added to vesicles to be kept intact or previously
disrupted. Protein A on lysed Staphylococcus aureus cells
(Pansorbin, Calbiochem; 100 jul of suspension) was used to
precipitate antibody-bound 12'I-labeled toxin-receptor com-
plexes. After 30 min at room temperature, the precipitate
was sedimented through 1 ml of 1 M sucrose and 1251 in the
pellets was determined in a Beckman y counter. This assay
depends on accessibility of the immobilized protein A to the
IgGs. IgGs that bind to the portion of AcChoR on the exter-
nal surface of the vesicles are accessible to protein A-S. qu-
reus, whereas IgGs that bind internally are inaccessible unr
less the vesicles are solubilized with detergent. Thus, even
vesicles that are somewhat permeable to macromoleculvs
(38, 39) give the same results as sealed vesicles in this assay.'
Electron Microscopy and Immunofluorescence. Membra~n
sheets from T. californica electroplax were prepared by slic,
ing fresh electric organ and further disrupting it by Pn;
stroke in a Dounce homogenizer (40). The tissue was washed
three times in tissue buffer (280 mM NaCl/3.0 mM KCl/I,8
mM MgCl2/300 mM urea/100 mM sucrose/5.5 mM glu-
cose/40 mM Hepes/1% BSA, pH 7.2) by sedimenting i"q
clinical centrifuge and then gently resuspending. All proce-
dures were executed at 40C. Aliquots of the tissue were jnu-
bated either with affinity-purified 8-273 or 3-350 or with cqr1-
trol mAb L-210 or L-111 at a dilution of 1:2 for 12 hr and then
washed four times in tissue buffer. Both fluorescein-coP'ju-;
gated goat anti-rabbit (or anti-rat) IgG and colloidal gpld-
conjugated goat anti-rabbit (or anti-rat) IgG were used as
second antibodies. For immunofluorescence, tissue was',ii-
cubated for 1 hr with the second antibody and rhodamine-
conjugated a-bungarotoxin, washed four times in tissue bufif
er, and then mounted on a slide with a cover slip for fluQres
cence microscopy. For colloidal gold labeling, samples were
incubated overnight with 5 nm colloidal gold conjugate4.,'ei'-
ther to goat anti-rabbit IgG or to goat anti-rat IgCG (Janssen
Pharmaceutica, Beerse, Belgium) and then washed OUr
times in tissue buffer. Tissue was fixed in 2% (vol/vol) gnld-
taraldehyde/100 mM sodium cacodylate for 1.5 hr on ice and
then washed three times in 100mM sodium cacodylate. $tA-
ples were post-stained with 2% (wt/vol) osmium tetrq-
ide/100 mM sodium cacodylate at room temperature, d~y-
drated in ethanol, and embedded in Epon (600C). Silvergiay
sections were adsorbed to cleaned copper grids, post-staiied
with 1% (wt/vol) uranyl acetate, and coated with carbhn.
Electron microscopy was carried out using an 80 kV acele't-
ating voltage on a Phillips EM-400 microscope.
RESULTS AND DISCUSSION
Immunoblots with either purified AcChoR or a crude mem-
brane extract of Torpedo electric organ showed that affinity-
purified antibodies 8-273 and 83-350 bind to the 8 and (3
chains, respectively, of the mature AcChoR. There was esg
sentially no cross-reactivity to the other chains of AcChbR
or to other proteins (Fig. 1). The amino acid sequences of all
four subunits were checked for homology with the synthetic
peptides at regions other than the COOH terminus or'the
cytoplasmic region near residue 350: no exact match of Morq
than three consecutive amino acids was found. The greatest
similarity of sequences occurred between the 8 chain peptidp
and the homologous COOH terminus of the y chain, thptlg
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FIG. 1. Immunoblots. Antibodies 8-273 (lanes a and d), (-350
(lanes b and e) and a rabbit anti-Torpedo AcChoR serum (lanes c and
f) were incubated with nitrocellulose blots of electrophoresed affini-
ty-purified AcChoR (lanes a-c) or a Triton X-100 extract of electric
organ prepared as for electron microscopy (lanes d-f), followed by
incubation with '25I-labeled-goat anti-rabbit IgG and autoradiogra-
phy.
no cross-reactivity was seen on immunoblots. Therefore, the
antibodies probably bind only to sections of the mature poly-
peptide chains that correspond to the DNA sequence on
which the peptides were based; in the case of &-273, this cor-
responds to the COOH terminus.
Binding of 6-273 to Torpedo AcChoR was measured using
a radioimmunoassay with the 125I-labeled peptide. From sat-
uration analysis of the binding of the iodinated peptide to the
anti-8 COOH-terminus antibody, an apparent association
constant of 3.3 x 109 M1 was obtained. The unlabeled pep-
tide caused 40% displacement of the labeled ligand at a con-
centration of 0.25 nM (Fig. 2). Sealed AcChoR vesicles
failed to compete with the labeled peptide even at a concen-
tration of 25 nM. On the other hand, vesicles made perme-
able by treatment with saponin competed very effectively,
causing 40% displacement of 125I-labeled peptide at a con-
centration of 10 nM. Reduced and carbamoylmethylated
(monomeric) AcChoR was used in all in vitro binding assays;
in immunoprecipitation, &-273 showed a strong preference
for monomeric over dimeric AcChoR (unpublished data).
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FIG. 2. Competition between the synthetic 8 C-terminal peptide
and AcChoR. 125I-labeled Ac[Gly516]8-subunit-(501-516) was incu-
bated with the antibody 8-273 at a 1:20,000 dilution for 24 hr at 200C
followed by competition with AcChoR in sealed intact vesicles (),
saponin-permeabilized AcChoR vesicles (A), and non-iodinated pep-
tide (W).
To determine directly the sidedness of binding to the Ac-
ChoR in outside-out vesicles, we used an immunoprecip-
itation assay that depends on accessibility pfbound antibody
to immobilized protein A. Two antibodies were used as con-
trols: mAb L-35, which binds to the main immunogenic re-
gion on the a chain on the synaptic side of the membrane;
and mAb F-88, which binds both By and 8 on the cytoplasmic
side. mAb L-35 gave 100% immunoprecipitation bf the 125i-
labeled receptors when incubated with either intact or deter-
gent-treated preparations. In contrast, mAb F-88 precipitat-
ed <10% of labeled AcChoR from intact vesicles, presum-
ably due to AcChoR in membrane sheets rather than in
vesicles. More than 55% were precipitated from detergent-
solubilized vesicles (Fig. 3). The failure to achieve 100% pre-
cipitation with mAb F-88 is unexplained; higher antibody
concentrations did not increase the amount of AcChoR pre-
cipitated, and the results were the same whether vesicles
were solubilized before or after application of the first anti-
body.
The pattern obtained with anti-8 COOH-terminus antibod-
ies (8-273) was essentially identical to that obtained with
mAb F-88: precipitation of AcChoR from intact vesicles in-
creased from 8% to 45% upon solubilization with cholate.
Similar results were obtained using /3350, with precipitation
of up to 26% of solubilized AcChoR. When intact but leaky
vesicles were substituted for saponin-treated vesicles, up to
=w50 of AcChoR could be precipitated by 8-273 or by F-88.
These results indicate that both 6-273 and /&350 recognize an
internal (cytoplasmic) site on the AcChoR.
To localize the sites of binding of the antibodies to the
AcChoR in tissue rather than vesicles and without recourse
to detergent treatment, we examined sections of Torpedo
electric organ by immuno-electron microscopy. Disrupted
tissue was incubated with anti-peptide antibody followed by
second antibody conjugated to colloidal gold. Basal lamina
and portions of presynaptic membrane with associated syn-
aptic vesicles were seen to adhere to the postsynaptic mem-
brane (Fig. 4) allowing its two sides to be unambiguously
identified. Both antibodies 6-273 and /&350 bound excclusive-
ly to the cytoplasmic side (Figs. 4 and 5). The results ob-
tained with the two antibodies, although similar, showed dif-
ferences in detail. ,-350 showed a relatively uniform distri-
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FIG. 3. In vitro binding assays. Intact AcChoR vesicles (V), sa-
ponin-permeabilized AcChoR vesicles (S), and AcChoR vesicles
solubilized in 2% sodium cholate (C) were incubated with antibody
8-273, F-88, or L-35, each at 1:200 dilution as explained in Methods.
AcChoR was labeled with 125"-labeled a-bungarotoxin and Ac-
ChoR-antibody complexes were precipitated by adsorption onto
protein A-S. aureus particles.
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FIG. 4. Electron micrographs showing binding of 5-273, anti-8 COOH-terminus antibody (A); L-210, a mAb that binds on the extracellular
portion of the AcChoR (B); antibody &-350, which binds to residues 350-358 of AcChoR a subunit (C); and L-111, a mAb that binds to the
cytoplasmic side of the T. californica postsynaptic membrane. Antibodies were visualized with 5 nm colloidal gold (seen as black beads)
conjugated to goat anti-rabbit IgG (or anti-rat IgG). Gold beads can be seen clearly on the cytoplasmic (c) side of the postsynaptic membrane
(indicated by arrow) in the case of antibodies B-273, P-350, and L-111, whereas antibody L-210 labels the synaptic side of the postsynaptic
membrane. Even labeling of the postsynaptic membrane was observed with all of the AcChoR antibodies tested with the exception of 5-273,
which appeared to label extensions of the postsynaptic membrane more heavily. The bar is equivalent to 2000 A and applicable to all four
micrographs. Sections were stained with uranyl acetate.
bution of label like, that seen with mAb L-111 (Fig. 4 C and
D), which binds to the cytoplasmic surface (32). 5-273
showed a more uneven distribution, suggesting that in some
regions the antigenic site may be physically or conformation-
ally less accessible. Both sides of the membrane were acces-
sible to anti-receptor antibodies as well as to gold-conjugated
second antibodies, since labeling of the synaptic side was
obtained with mAb L-210, which binds to an extracellular
site on the AcChoR (Fig. 4B). Negligible labeling was seen in
the absence of first antibody and, in all cases, membranes
other than the postsynaptic membrane showed essentially no
labeling. The specificity of binding of the antibodies to the
postsynaptic membrane was confirmed by immunofluores-
cence (not shown). Both antibodies &-273 and 3-350 showed
a staining pattern, revealed by fluorescein-conjugated sec-
ond antibody, that was identical to that seen with rhoda-
mine-conjugated a-bungarotoxin.
CONCLUSION
Our results show that the COOH terminus of the subunit of
AcChoR and the sequence 350-358 of the (B chain are located
on the cytoplasmic side of the postsynaptic membrane, indi-
catitig that the polypeptide chain ofAcChoR subunit cross-
es the lipid bilayer an odd number of times. The strong se-
quence homology between chains of AcChoR suggests a
common topology for all of the subunits (13); thus, finding
.
350 on the cytoplasmic side implies that there are an even
number of membrane crossings between residue 358 and the
COOH terminus in the common threading pattern (Fig. 6).
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FIG. 5. Electron micrographs showing binding of 5-273 to the
cytoplasmic (c) side of the postsynaptic membrane (indicated by ar-
row). The stain is uranyl acetate. (Bar = 1000 A.)
FIG. 6. Schematic drawing showing the predicted secondary
structure for the receptor subunits and the "five-crossing" model of
polypeptide chain threading through the bilayer (15).
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FIb. 7. A representation of the postulated channel-forming se-
quences as arranged around the central ion channel. Charges inside
the transmembrane region of the proposed channel are indicated.
Note that charge alternates between planes of positive and negative
charge, and that the net charge in the indicated region is zero. This
structure can preserve a water-filled channel inside the AcChoR ro-
sette.
Within each subunit sequence there are only four obviously
hydrophobic regions long enough to span the membrane (10,
12, 13). A fifth sequence, identified by amphipathic analysis,
has also been postulated to span the membrane. This se-
quence can form an a-helix that is hydrophobic on one side
and highly charged on the other (3, 15, 18). In conjunction,
the homologous sequences from the five subunits, presented
as armiphipathic helices oriented so that the charged side of
each helix faces the center, could form the ion channel
across the most hydrophobic part of the plasma membrane.
Our results provide evidence that there must be a fifth mem-
brane crossing in addition to the four hydrophobic spanning
fhgions. Experiments that rely on detergent to enhance anti-
$otly.labeling of AcChoR cannot be proof of a cytoplasmic
Opitope, because the possibility of loosening the target pep-
tide it the exterior surface, also leading to enhancement,
c*Enbt be excluded. Our results are consistent with the idea
that the ion channel in the AcChoR is formed by five ho-
mologous amphipathic helices, each of which contributes
charged residues to the lining of a water-filled ion-conduct-
ingchannel (Fig. 7). Model-building and energy calculations
with the program AMBER (41) show that this structure can
catalyze the passage of hydrated sodium ions or organic cat-
ionsj known to pass through the AcChoR channel (unpub-
lishod observations).
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